Prognostic significance of micrometastasis in non-small-cell lung cancer

Clinical Lung Cancer

Volumn 5, Issue 4, 2004, Pages 214-225

  Coello, Michael C ^a   Luketich, James D ^a,b   Litle, Virginia R ^a   Godfrey, Tony E ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Bone marrow; Lymph nodes; Occult tumor cells; Pathologic staging

Indexed keywords

BIOCHEMICAL MARKER; CARCINOEMBRYONIC ANTIGEN; K RAS PROTEIN; KERATIN ANTIBODY; MONOCLONAL ANTIBODY; MUCIN 1; POLYCLONAL ANTIBODY; PROTEIN P53; VASCULOTROPIN;

BONE MARROW BIOPSY; BONE MARROW METASTASIS; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CORRELATION COEFFICIENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MEDICAL DECISION MAKING; MEDICAL LITERATURE; OCCULT CANCER; OUTCOMES RESEARCH; PREDICTION; PROGNOSIS; RELIABILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT PLANNING; TUMOR CELL;

EID: 1542360634     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2004.n.002     Document Type: Review

References (69)

1. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111:1710-1717.
2. Cancer: Principles & Practice of Oncology, 56th ed. In: Devita DV, Hellman S, Rosenberg SA, eds. Philadelphia, PA: Lippincott Williams & Wilkins, 2001.
3. Lopez-Encuentra A, Bulzebruck H, Feinstein AR, et al. Tumor staging and classification in lung cancer. Summary of the international symposium. Madrid, Spain, 3-4 December 1999. Lung Cancer 2000; 29:79-83.
4. Mountain CF. The international system for staging lung cancer. Semin Surg Oncol 2000; 18:106-115.
5. Mountain CF. Staging classification of lung cancer. A critical evaluation. Clin Chest Med 2002; 23:103-121.
6. Bostick PJ, Chatterjee S, Chi DD, et al. Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients. J Clin Oncol 1998; 16:2632-2640.
7. Mitas M, Mikhitarian K, Walters C, et al. Quantitative real-time RT-PCR detection of breast cancer micrometastasis using a multigene marker panel. Int J Cancer 2001; 93:162-171.
8. Liefers GJ, Cleton-Jansen AM, van de Velde CJ, et al. Micrometastases and survival in stage II colorectal cancer. N Engl J Med 1998; 339:223-228.
9. Mitas M, Cole DJ, Hoover L, et al. Real-time reverse transcription-PCR detects KS1/4 mRNA in mediastinal lymph nodes from patients with non-small cell lung cancer. Clin Chem 2003; 49:312-315.
10. Godfrey TE, Raja S, Finkelstein SD, et al. Prognostic value of quantitative reverse transcription-polymerase chain reaction in lymph node-negative esophageal cancer patients. Clin Cancer Res 2001; 7:4041-4048.
11. Jiao X, Krasna MJ. Clinical significance of micrometastasis in lung and esophageal cancer: a new paradigm in thoracic oncology. Ann Thorac Surg 2002; 74:278-284.
12. Perez-Cardona JH, Ordonez NG, Fosella FV. Lymph node micrometastases in non-small-cell lung cancer: clinical applications. Clin Lung Cancer 2000; 2:116-120.
13. Chen ZL, Peru S, Holmes EC, et al. Frequency and distribution of occult micrometastases in lymph nodes of patients with non-small-cell lung carcinoma. J Natl Cancer Inst 1993; 85:493-498.
14. Nicholson AG, Graham AN, Pezzella F, et al. Does the use of immunohistochemistry to identify micrometastases provide useful information in the staging of node-negative non-small cell lung carcinomas? Lung Cancer 1997; 18:231-240.
15. Dobashi K, Sugio K, Osaki T, et al. Micrometastatic P53-positive cells in the lymph nodes of non-small-cell lung cancer: prognostic significance. J Thorac Cardiovasc Surg 1997; 114:339-346.
16. Maruyama R, Sugio K, Mitsudomi T, et al. Relationship between early recurrence and micrometastases in the lymph nodes of patients with stage I non-small-cell lung cancer. J Thorac Cardiovasc Surg 1997; 114:535-543.
17. Kubuschok B, Passlick B, Izbicki JR, et al. Disseminated tumor cells in lymph nodes as a determinant for survival in surgically resected non-small-cell lung cancer. J Clin Oncol 1999; 17:19-24.
18. Ohta Y, Oda M, Wu J, et al. Can tumor size be a guide for limited surgical intervention in patients with peripheral non-small cell lung cancer? Assessment from the point of view of nodal micrometastasis. J Thorac Cardiovasc Surg 2001; 122:900-906.
19. Osaki T, Oyama T, Gu CD, et al. Prognostic impact of micrometastatic tumor cells in the lymph nodes and bone marrow of patients with completely resected stage I non-small-cell lung cancer. J Clin Oncol 2002; 20:2930-2936.
20. Gu CD, Osaki T, Oyama T, et al. Detection of micrometastatic tumor cells in pN0 lymph nodes of patients with completely resected nonsmall cell lung cancer: impact on recurrence and Survival. Ann Surg 2002; 235:133-139.
21. Traweek ST, Liu J, Battifora H. Keratin gene expression in non-epithelial tissues. Detection with polymerase chain reaction. Am J Pathol 1993; 142:1111-1118.
22. Hashimoto T, Kobayashi Y, Ishikawa Y, et al. Prognostic value of genetically diagnosed lymph node micrometastasis in non-small cell lung carcinoma cases. Cancer Res 2000; 60:6472-6478.
23. Izbicki JR, Passlick B, Hosch SB, et al. Mode of spread in the early phase of lymphatic metastasis in non-small-cell lung cancer: significance of nodal micrometastasis. J Thorac Cardiovasc Surg 1996; 112:623-630.
24. Passlick B. Detection of disseminated lung cancer cells in lymph nodes by monoclonal antibodies: impact on staging and prognosis. Ann Ital Chir 1999; 70:839-840.
25. Passlick B, Izbicki JR, Kubuschok B, et al. Detection of disseminated lung cancer cells in lymph nodes: impact on staging and prognosis. Ann Thorac Surg 1996; 61:177-182.
26. Passlick B, Izbicki JR, Kubuschok B, et al. Immunohistochemical assessment of individual tumor cells in lymph nodes of patients with non-small-cell lung cancer. J Clin Oncol 1994; 12:1827-1832.
27. Ohta Y, Nozaki Z, Nozawa H, et al. The predictive value of vascular endothelial growth factor and nm23 for the diagnosis of occult metastasis in non-small cell lung cancer. Jpn J Cancer Res 2001; 92:361-366.
28. Ohta Y, Nozawa H, Tanaka Y, et al. Increased vascular endothelial growth factor and vascular endothelial growth factor-c and decreased nm23 expression associated with microdissemination in the lymph nodes in stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 2000; 119:804-813.
29. Wu J, Ohta Y, Minato H, et al. Nodal occult metastasis in patients with peripheral lung adenocarcinoma of 2.0 cm or less in diameter. Ann Thorac Surg 2001; 71:1772-1777.
30. Salerno CT, Frizelle S, Niehans GA, et al. Detection of occult micrometastases in non-small cell lung carcinoma by reverse transcriptase-polymerase chain reaction. Chest 1998; 113:1526-1532.
31. D'Cunha J, Corfits AL, Herndon JE II, et al. Molecular staging of lung cancer: real-time polymerase chain reaction estimation of lymph node micrometastatic tumor cell burden in stage I non-small cell lung cancer - preliminary results of Cancer and Leukemia Group B Trial 9761. J Thorac Cardiovasc Surg 2002; 123:484-491.
32. Ahrendt SA, Yang SC, Wu L, et al. Molecular assessment of lymph nodes in patients with resected stage I non-small cell lung cancer: preliminary results of a prospective study. J Thorac Cardiovasc Surg 2002; 123:466-473.
33. Brugger W, Buhring HJ, Grunebach F, et al. Expression of MUC-1 epitopes on normal bone marrow: implications for the detection of micrometastatic tumor cells. J Clin Oncol 1999; 17:1535-1544.
34. Dent GA, Civalier CJ, Brecher ME, et al. MUC1 expression in hematopoietic tissues. Am J Clin Pathol 1999; 111:741-747.
35. Dearnaley DP, Ormerod MG, Sloane JP, et al. Detection of isolated mammary carcinoma cells in marrow of patients with primary breast cancer. J R Soc Med 1983; 76:359-364.
36. Redding WH, Coombes RC, Monaghan P, et al. Detection of micrometastases in patients with primary breast cancer. Lancet 1983; 2:1271-1274.
37. Coombes RC, Dearnaley DP, Buckman R, et al. Detection of bone metastases in patients with breast cancer. Invas Metastasis 1982; 2:177-184.
38. Sloane JP, Ormerod MG. Distribution of epithelial membrane antigen in normal and neoplastic tissues and it value in diagnostic tumor pathology. Cancer 1981; 47:1786-1795.
39. Cote RJ, Beattie EJ, Chaiwun B, et al. Detection of occult bone marrow micrometastases in patients with operable lung carcinoma. Ann Surg 1995; 222:415-423.
40. Ohgami A, Mitsudomi T, Sugio, K, et al. Micrometastatic tumor cells in the bone marrow of patients with non-small cell lung cancer. Ann Thorac Surg 1997; 64:363-367.
41. Hsu CS, Chen CY, Kwang PC, et al. Bone-marrow microinvolvement in non-small cell lung cancer is not a reliable indicator of tumour recurrence and prognosis. Eur J Surg Oncol 2000; 26:691-695.
42. Poncelet AJ, Weynand B, Ferdin F, et al. Bone marrow micrometastasis might not be a short-term predictor of survival in early stages non-small cell lung carcinoma. Eur J Cardiothorac Surg 2001; 20:481-488.
43. Sugio K, Kase S, Sakada T, et al. Micrometastasis in the bone marrow of patients with lung cancer associated with a reduced expression of E-cadherin and beta-catenin: risk assessment by immunohistochemistry. Surgery 2002; 131:S226-S231.
44. Passlick B, Kubuschok B, Izbicki JR, et al. Isolated tumor cells in bone marrow predict reduced survival in node-negative non-small cell lung cancer. Ann Thorac Surg 1999; 68:2053-2058.
45. Simmons R, Hoda S, Osborne M. Bone marrow micrometastases in breast cancer patients. Am J Surg 2000; 180:309-312.
46. Braun S, Pantel K, Muller P, et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 2000; 342:525-533.
47. Diel IJ, Kaufmann M, Costa SD, et al. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst 1996; 88:1652-1658.
48. Landys K, Persson S, Kovarik J, et al. Prognostic value of bone marrow biopsy in operable breast cancer patients at the time of initial diagnosis: results of a 20-year median follow-up. Breast Cancer Res Treat 1998; 49;27-33.
49. Weckermann D, Muller P, Wawroschek F, et al. Micrometastases of bone marrow in localized prostate cancer: correlation with established risk factors. J Clin Oncol 1999; 17:3438-3443.
50. Gao CL, Dean RC, Pinto A, et al. Detection of circulating prostate specific antigen expressing prostatic cells in the bone marrow of radical prostatectomy patients by sensitive reverse transcriptase polymerase chain reaction. J Urol 1999; 161:1070-1076.
51. Kollermann J, Heseding B, Helpap B, et al. Comparative immunocytochemical assessment of isolated carcinoma cells in lymph nodes and bone marrow of patients with clinically localized prostate cancer. Int J Cancer 1999; 84:145-149.
52. Kufer P, Zippelius A, Lutterbuse R, et al. Heterogeneous expression of MAGE-A genes in occult disseminated tumor cells: a novel multimarker reverse transcription-polymerase chain reaction for diagnosis of micrometastatic disease. Cancer Res 2002; 62:251-261.
53. Tortola S, Steinert R, Hantschick M, et al. Discordance between K-ras mutations in bone marrow micrometastases and the primary tumor in colorectal cancer. J Clin Oncol 2001; 19:2837-2843.
54. Relihan N, McGreal G, Kelly J, et al. Combined sentinel lymph-node mapping and bone-marrow micrometastatic, analysis for improved staging in breast cancer. Lancet 1999; 354:129-130.
55. Mattioli S, D'Ovidio F, Tazzari P, et al. Iliac crest biopsy versus rib segment resection for the detection of bone marrow isolated tumor cells from lung and esophageal cancer. Eur J Cardiothorac Surg 2001; 19:576-579.
56. Kawano R, Hata E, Ikeda S, et al. Micrometastasis to lymph nodes in stage I left lung cancer patients. Ann Thorac Surg 2002; 73:1558-1562.
57. Asamura H, Nakayama H, Kondo H, et al. Lobe-specific extent of systematic lymph node dissection for non-small cell lung carcinomas according to a retrospective study of metastasis and prognosis. J Thorac Cardiovasc Surg 1999; 117:1102-1111.
58. Izbicki JR, Passlick B, Pantel K, et al. Effectiveness of radical systematic mediastinal lymphadenectomy in patients with resectable non-small cell lung cancer: results of a prospective randomized trial. Ann Surg 1998; 227:138-144.
59. Passlick B, Kubuschock B, Sienel W, et al. Mediastinal lymphadenectomy in non-small cell lung cancer: effectiveness in patients with or without nodal micrometastases - results of a preliminary study. Eur J Cardiothorac Surg 2002; 21:520-526.
60. Martini N, Flehinger BJ, Zaman MB, et al. Results of resection in non-oat cell carcinoma of the lung with mediastinal lymph node metastases. Ann Surg 1983; 198:386-397.
61. Martini N, Flehinger BJ, Zaman MB, et al. Results of surgical treatment in N2 lung cancer. World J Surg 1981; 5:663-666.
62. Keller SM, Adak S, Wagner H, et al. Mediastinal lymph node dissection improves survival in patients with stages II and IIIa non-small cell lung cancer. Eastern Cooperative Oncology Group. Ann Thorac Surg 2000; 70:358-365.
63. Naruke T, Goya T, Tsuchiya R, et al. The importance of surgery to non-small cell carcinoma of lung with mediastinal lymph node metastasis. Ann Thorac Surg 1988; 46:603-610.
64. Pantel K, Schlimok G, Braun S, et al. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 1993; 85:1419-1424.
65. Passlick B. Micrometastases in non-small cell lung cancer (NSCLC). Lung Cancer 2001; 34(suppl 3):S25-S29.
66. Iwao K, Watanabe T, Fujiwara Y, et al. Isolation of a novel human lung-specific gene, LUNX, a potential molecular marker for detection of micrometastasis in non-small-cell lung cancer. Int J Cancer 2001; 91:433-437.
67. Betz C, Papadopoulos T, Buchwald J, et al. Surfactant protein gene expression in metastatic and micrometastatic pulmonary adenocarcinomas and other non-small cell lung carcinomas: detection by reverse transcriptase-polymerase chain reaction. Cancer Res 1995; 55:4283-4286.
68. Pantel K, Dickmanns A, Zippelius A, et al. Establishment of micrometastatic carcinoma cell lines: a novel source of tumor cell vaccines. J Natl Cancer Inst 1995; 87:1162-1168.
69. Hosch S, Kraus J, Scheunemann P, et al. Malignant potential and cytogenetic charactcristics of occult disseminated tumor cells in esophageal cancer. Cancer Res 2000; 60:6836-6840.